ImmuPharma Investor Relations Material
Latest events
H1 2025
6 Aug, 2025
H2 2024
19 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImmuPharma plc
Access all reports
ImmuPharma plc is a pharmaceutical company focused on the research, development, and commercialization of novel peptide-based drugs. The company specializes in therapies for autoimmune and inflammatory diseases, with activities spanning early-stage discovery through to clinical development. Its research is supported by collaborations with scientific institutions and licensing partnerships. The company is headquartered in London, United Kingdom, and its shares are listed on the AIM.
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
IMM
Country
🇬🇧 United Kingdom